TLDR
- AstraZeneca reportedly offered about $10 billion for Rhythm Pharmaceuticals
- The non-binding bid is worth up to $134 a share, including milestone payments
- Rhythm (RYTM) closed up 28% at $110.68 on Wednesday
- AstraZeneca (AZN) rose about 3% on the news
- Neither company has commented on the offer
Rhythm Pharmaceuticals (RYTM) jumped 28% to close at $110.68 on Wednesday. The move came after reports that AstraZeneca (AZN) wants to buy the company.
AstraZeneca stock also moved higher, gaining about 3% on the day. Its market value stands at roughly $292 billion.
Reuters reported the offer is worth about $10 billion. Three people familiar with the matter shared the details.
AstraZeneca $AZN offered about $124 a share, or roughly $10 billion, for obesity drugmaker Rhythm Pharmaceuticals last month, the WSJ reports pic.twitter.com/5jTvKf3yK5
— Wall St Engine (@wallstengine) November 4, 2026
The non-binding proposal reaches as much as $134 a share. That figure includes payments tied to milestones.
The Price Gap
Rhythm’s close of $110.68 sits below the top of the reported range. The company now carries a market cap of about $7.64 billion.
The Wall Street Journal reported earlier in the day on a separate number. It said AstraZeneca offered $124 a share last month.
The Reuters sources did not explain the difference between the two figures. The higher $134 number includes milestone payments, which may account for part of it.
AstraZeneca would run the deal through Alexion. That is its rare-disease unit, which it bought for $39 billion in 2021.
An AstraZeneca spokesperson declined to comment. Rhythm did not respond to requests for comment.
Why Rhythm Fits
Rhythm develops treatments for rare neuroendocrine and metabolic disorders. Its lead drug is Imcivree.
In March, the FDA expanded Imcivree’s use. It became the first U.S.-approved treatment for a rare form of obesity caused by brain damage.
The company is also working on therapies for other rare conditions. Its focus is on genetic forms of obesity, not the broad weight-loss market.
That market is still a big draw for drugmakers. Novo Nordisk and Eli Lilly have driven strong demand, and some forecasts see sales topping $100 billion a year over the next decade.
AstraZeneca has shown interest in Rhythm before. The Wall Street Journal said it renewed its pursuit in recent months.
CEO Pascal Soriot is trying to turn investor focus back to growth. The past few months were rough, with clinical trial setbacks and reports of a possible deal with Bristol Myers Squibb weighing on the stock.
Nothing is final. The offer is reported, not announced, and no agreement has been confirmed by either side.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
